FRI0494 Secukinumab Provides Rapid and Sustained Pain Relief in Psoriatic Arthritis: 2-Year Results From the Future 2 Study

doi 10.1136/annrheumdis-2017-eular.5086

Full Text

Abstract

Available in

Date

Authors

Publisher

BMJ Publishing Group Ltd and European League Against Rheumatism

Related search

Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Psoriatic Arthritis: Final 5‐year Results From the Phase 3 FUTURE 1 Study

ACR Open Rheumatology
2019English

THU0369 Secukinumab 150mg Provides Sustained Improvements in the Signs and Symptoms of Active Ankylosing Spondylitis With High Retention Rate: 3-Year Results From Phase Iii Trial, Measure 2

2017English

Progression of Fibromyalgia: Results From a 2-Year Observational Fibromyalgia and Chronic Pain Study in the US

Journal of Pain Research
AnesthesiologyPain Medicine
2016English

Interleukin-17inhibition With Secukinumab Improves Sudomotor Dysfunction in Psoriatic Arthritis

International Journal of Pharmacy and Pharmaceutical Sciences
PharmacologyPharmaceutical Science
2018English

Real-World Data on Secukinumab Use for Psoriatic Arthritis and Ankylosing Spondylitis

Therapeutic Advances in Musculoskeletal Disease
RheumatologyOrthopedicsSports Medicine
2019English

Certolizumab Pegol Is Associated With Long-Term Improvements in Patient-Reported Outcomes in Psoriatic Arthritis: 4-Year Outcomes From the Rapid-Psa Study

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2016English

Cardiovascular Risk Management in Rheumatoid and Psoriatic Arthritis: Online Survey Results From a National Cohort Study

BMC Rheumatology
Rheumatology
2018English

Decreased Use of Glucocorticoids in Biological-Experienced Patients With Rheumatoid Arthritis Who Initiated Intravenous Abatacept: Results From the 2-Year ACTION Study

RMD Open
RheumatologyAllergyImmunology
2016English

Matching-Adjusted Indirect Comparison: Secukinumab Versus Infliximab in Biologic-Naive Patients With Psoriatic Arthritis

Journal of Comparative Effectiveness Research
Health Policy
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy